What are the maximum oral and intravenous doses of hydralazine that can be administered within a 24‑hour period in an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of Hydralazine in 24 Hours

For intravenous hydralazine, the maximum dose is 20 mg per single administration, repeated every 4-6 hours as needed, with no explicit 24-hour maximum stated in guidelines, though the FDA label indicates doses of 20-40 mg repeated as necessary. 1 For oral hydralazine, the maximum daily dose is 300 mg in adults (7.5 mg/kg/day up to 200 mg/day in children). 2

Intravenous Dosing

The 2017 ACC/AHA hypertension guidelines consistently specify for IV hydralazine: Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every 4-6 hours as needed. 3, 4, 5, 6, 4, 3

The FDA label for IV hydralazine states: "The usual dose is 20 to 40 mg, repeated as necessary. Certain patients (especially those with marked renal damage) may require a lower dose." 1 The label emphasizes that most patients can be transferred to oral hydralazine within 24-48 hours.

Key Considerations for IV Use:

  • Onset of action: 10-30 minutes, with effects lasting 2-4 hours 3, 4, 5
  • Unpredictability of response and prolonged duration make hydralazine a less desirable first-line agent for acute hypertensive emergencies 3, 4, 5
  • Lower doses required in patients with renal impairment 1
  • Should be used immediately after vial opening and not added to infusion solutions 1

Oral Dosing

For chronic oral therapy:

  • Adults: Maximum 300 mg/day, typically divided into multiple doses 7, 8
  • Children: 7.5 mg/kg/day up to 200 mg/day, given four times daily 2

The evidence shows that 300 mg daily can be given effectively in 2 divided doses rather than 4, with similar blood pressure control and fewer fluctuations. 7

Special Populations

Pregnancy/Preeclampsia: The 2025 ACC/AHA guidelines specify for acute treatment: 5 mg IV or IM, then 5-10 mg IV every 20-40 minutes to a maximum cumulative dosage of 20 mg; or constant infusion of 0.5-10 mg/h. 9 Higher or frequent dosing is associated with maternal hypotension and abnormal fetal heart rate tracings. 9

Critical Safety Warnings

  • Hypotension risk: IV hydralazine frequently causes excessive blood pressure drops, particularly in the inpatient setting where it's often inappropriately used for asymptomatic hypertension 10, 11
  • Adverse effects: Tachycardia, fluid retention, and lupus-like syndrome (in slow acetylators with chronic use) 2
  • Acetylator phenotype: Slow acetylators require lower doses due to higher plasma levels 12, 8
  • Recent evidence shows 69% of IV hydralazine use in hospitals lacks appropriate indications, leading to hypotension, acute kidney injury, and ICU transfers 10

Practical Algorithm

For hypertensive emergencies (IV route):

  1. Start with 10 mg slow IV infusion
  2. Maximum single dose: 20 mg
  3. Repeat every 4-6 hours only if needed
  4. Transition to oral therapy within 24-48 hours 1

For chronic hypertension (oral route):

  1. Start low (25-50 mg twice daily)
  2. Titrate based on response
  3. Maximum: 300 mg/day in divided doses
  4. Consider acetylator status for dosing adjustments 8

The guidelines do not specify an absolute 24-hour maximum for IV hydralazine, but the dosing interval of every 4-6 hours with 20 mg maximum per dose suggests a practical upper limit of approximately 80-120 mg in 24 hours if given at maximum frequency, though this should be avoided in favor of more predictable agents for sustained blood pressure control.

References

Research

Duration of hydralazine action in hypertension.

Clinical pharmacology and therapeutics, 1975

Research

Hydralazine dose-response curve analysis.

Journal of pharmacokinetics and biopharmaceutics, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.